Fnx Performance products are intended strictly for qualified in vitro laboratory research. For Research Use Only. Not for human or animal consumption. Not for compounding or therapeutic application.
NAD+, Dinucleotide coenzyme
A dinucleotide coenzyme (not a peptide) central to mitochondrial energy, DNA repair, and sirtuin signaling, which declines with age, the basis for the supplementation rationale.
Shop this peptide
A coenzyme in every cell, central to energy production, DNA repair, and sirtuins. The catch: it's too large and charged to enter cells intact, so it must be broken into precursors first.
Raise blood NAD+
Energy / wellness
Mechanistic basis
Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.
Trammell SAJ, et al.
First human pharmacokinetic trial of the NAD+ precursor NR: single 100-1000 mg doses produced dose dependent rises in the blood NAD+ metabolome.
Marketed for energy, anti aging, cognitive clarity, and metabolic health. A 2026 PRISMA systematic review found no eligible trials evaluating IV/IM/SC NAD+ itself for anti aging/wellness outcomes. Better human data exists for oral precursors (NR, NMN). For NAD+ injection specifically there is essentially no controlled efficacy evidence.
IV NAD+ is generally well tolerated but infusion rate dependent (too fast causes flushing, chest tightness, nausea). Sourcing/sterility is the dominant practical risk.
No well established absolute contraindications for short term use in healthy adults; caution in pregnancy (no data) and infusion reaction history.
Sold as supplement / wellness clinic IV; injectable NAD+ is not an FDA approved drug. Oral NR (Niagen) has GRAS status. WADA: not prohibited (endogenous coenzyme).
Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. For medical questions, consult a qualified physician.